vaccines

an Open Access Journal by MDPI

IMPACT FACTOR 7.8

Indexed in: PubMed

CITESCORE 7.0

Vaccines against Flaviviruses and Alphaviruses: Recent Advances and Future Challenges

Guest Editors:

Dr. Young Chan Kim
1. The Jenner Institute, ORCRB, Nuffield Department of Medicine, University of Oxford, Roosevelt Drive, Oxford OX3 7DQ, UK
2. Division of Structural Biology, Wellcome Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK

Dr. Arturo Reyes-Sandoval
1. The Jenner Institute, ORCRB, Nuffield Department of Medicine, University of Oxford, Roosevelt Drive, Oxford OX3 7DQ, UK
2. Instituto Politécnico Nacional, IPN. Av. Luis Enrique Erro s/n. Unidad Adolfo López Mateos, Mexico City, Mexico

Message from the Guest Editors

The mosquito-borne viruses such as Dengue (DENV), Zika (ZIKV) and Chikungunya (CHIKV) viruses have emerged in recent decades affecting millions of people worldwide. These flaviviruses and alphaviruses can be classified into a broader category of arboviruses, and they cause significant disease burdens and public health concerns. Vaccine development against arboviruses has experienced swift progress after the sudden (re)emergence of cases of DENV, CHIKV and ZIKV in the last two decades. Despite the fact that there are no licensed vaccines against ZIKV and CHIKV, the wide range of vaccine platforms including both classic and new approaches such as inactivated and attenuated, proteins, virus-like particles (VLPs), viral vectors, DNA and mRNA are currently being tested in pre-clinical studies and in clinical trials which could lead to the future licensing of vaccines.

This Special Issue will feature vaccines against flaviviruses and alphaviruses of medical importance in humans with a particular focus on the design, development and validation of new vaccine candidates and the animal model.

Deadline for manuscript submissions:
30 June 2024

vaccines

IMPACT FACTOR 7.8 | Indexed in: PubMed | CITESCORE 7.0

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp
Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com